Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/3079% below fair value

$1.64+0.05 (+3.14%)

Close on Nov 13, 2026Market cap $51.56MP/E 4.6Yield –

Actinium Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Actinium Pharmaceuticals's EV/EBITDA was 1.4× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.4×	–

Parsed from the XBRL in Actinium Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Aug 11, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ATNM.

Operating margin10617.8% · median -12448.3%

Net margin12564.4% · median -9807.3%

Advertisement
300 × 250

See a number that looks wrong?